Scientists on March 31 published the first complete human genome, filling in gaps remaining after previous efforts while offering new promise in the search for clues regarding disease-causing mutations and genetic variation among the world’s 7.9 billion people.

Allogene Therapeutics is halting the clinical trial for the company’s AlloCAR T cancer therapy after finding some chromosomal abnormality in a patient.

In this webinar, Dr. Benjamin Darbro and Alyssa Hahn will discuss how their organization is using Natural Language Processing to transform unstructured source data into clinical and research decision support insights.

Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.

Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder.

Shares of Ultragenyx sharply climbed after the company announced positive results from its Phase III study of burosumab in adults with X-linked hypophosphatemia (XLH).